Abstract 178P
Background
Liquid biopsy (LBx) based comprehensive genomic profiling (CGP) is increasingly used in clinical practice. The sensitivity of LBx is influenced by levels of circulating tumor DNA (ctDNA), but limited data is available correlating ctDNA levels with clinical parameters and their effect on detecting distinct genomic alterations in metastatic colorectal cancer (mCRC).
Methods
LBx using FoundationOne Liquid CDx was performed on plasma ctDNA at baseline in patients with RAS/BRAFV600E wild type (WT) mCRC enrolled in the CAPRI-2 GOIM trial.
Results
Among 205 patients with available baseline LBx, median ctDNA tumor fraction (TF) was 25% (range, 0.1-86%). ctDNA TF was higher among patients presenting with isolated liver involvement (n=68, ctDNA 34.5% [IQR 15.0-54.2]) or liver with other metastatic sites (n=90, ctDNA 30.0% [IQR 9.2-56.3]) as compared to those showing only lung (n=11, ctDNA 1.3% [IQR 1.0-2.3]; P<0.001) or lymph nodes involvement (n=13, ctDNA 1.7% [IQR 1.23-37.5]; P<0.001). ctDNA TF positively correlated with higher number of metastatic sites (≥3 anatomical sites: ctDNA 51% [IQR 17-66.5] vs. 1-2 sites: ctDNA 22% [IQR 2.3-49]; P<0.001), albeit only liver involvement (P<0.001) but not the number of anatomical sites (P=0.16) associated with higher ctDNA TF in the multivariable model. Samples showing copy number variants (CNV) showed higher ctDNA TF (LBx amplifications (n=64): ctDNA 45% [IQR 25-58.8] vs. 16% [IQR 1.7-48.5]; P<0.001; LBx deletions (n=12): ctDNA 56% [IQR 46.8-68.2] vs. 25% [IQR 3.3-51.0]; P<0.001), with no deletions and only 4 amplifications detected among samples showing a ctDNA TF below 10%. Patients showing a high Tumor mutational burden (TMB) (n=20) showed a numerical higher ctDNA TF (ctDNA 37.5% [IQR 16.5 vs. 56.4] vs. 28% [IQR 4.05-51.2]; P=0.08), with only one TMB-high case showing a ctDNA TF below 10%.
Conclusions
ctDNA levels depend on metastatic sites, with significantly lower levels in patients without liver involvement. Distinct alteration classes exhibit distinct analytical sensitivity, with CNV requiring higher ctDNA levels for detection.
Editorial acknowledgement
Clinical trial identification
EudraCT 2020-003008-15; NCT05312398.
Legal entity responsible for the study
The authors.
Funding
The CAPRI 2-GOIM clinical trial is partially supported by a research grant from Merck KGaA Italy.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
15P - Germline predictors of recurrence in patients with ER-positive and HER2-negative breast cancer: A GWAS analysis of multiple cohorts totaling 10,640 patients
Presenter: Emma Turcotte
Session: Cocktail & Poster Display session
Resources:
Abstract
16P - The role of systemic immunity in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy
Presenter: Chiara Molinari
Session: Cocktail & Poster Display session
Resources:
Abstract
17P - Development of an exo-miRNA panel for metastasis prediction in breast cancer
Presenter: Shafiqa Siddique
Session: Cocktail & Poster Display session
Resources:
Abstract
18P - Molecular characterization of circulating tumor cells in metastatic breast cancer using shallow whole genome sequencing
Presenter: Michela Bulfoni
Session: Cocktail & Poster Display session
Resources:
Abstract
19P - Single-cell transcriptomic and cell-cell communication profiles in breast cancer responders to chemotherapy or chemo-immunotherapy
Presenter: Marcela Carausu
Session: Cocktail & Poster Display session
Resources:
Abstract
20P - Distinctive genomic profile of lymph node profile and distant metastasis in papillary thyroid cancer
Presenter: Sara Gil-Bernabé
Session: Cocktail & Poster Display session
Resources:
Abstract
21P - Improving early cancer screening efficacy by adjusting tumor burden spectrum bias of liquid biopsy biomarkers
Presenter: Weituo Zhang
Session: Cocktail & Poster Display session
Resources:
Abstract
22P - Comparative analysis of miRNA biomarkers in liquid-based cytology and plasma for early detection of high-grade cervical intraepithelial neoplasia
Presenter: Stéphanie Calfa
Session: Cocktail & Poster Display session
Resources:
Abstract
23P - Unraveling predictive transcriptomic signatures of anti-EGFR therapy response in RAS/BRAF wild-type metastatic colorectal cancer
Presenter: Ana Regina de Abreu
Session: Cocktail & Poster Display session
Resources:
Abstract
24P - Integrated proteogenomic approach for discovering potential biomarkers in urothelial carcinoma of the bladder
Presenter: PONGSAKORN CHOOCHUEN
Session: Cocktail & Poster Display session
Resources:
Abstract